International – Study shows AZ’s COVID-19 jab did not increase the rate of rare blood clots after second dose

AstraZeneca’s COVID-19 vaccine – Vaxzevria – did not increase the rate of rare blood clots with low platelets after the second dose, according to a new study.

The analysis – published in The Lancet – was conducted using AZ’s global safety database, which captures all spontaneously reported adverse events from the real-world use of its medicines and vaccines across the globe.

According to the data demonstrated the estimated rate of the rare blood clotting disorder, known as thrombosis with thrombocytopenia syndrome (TTS), following the second dose of the vaccine was 2.3 per million vaccinees, compared to the background rate in an unvaccinated population…